These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25267606)

  • 1. Is residential treatment effective for opioid use disorders? A longitudinal comparison of treatment outcomes among opioid dependent, opioid misusing, and non-opioid using emerging adults with substance use disorder.
    Schuman-Olivier Z; Claire Greene M; Bergman BG; Kelly JF
    Drug Alcohol Depend; 2014 Nov; 144():178-85. PubMed ID: 25267606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment.
    Savant JD; Barry DT; Cutter CJ; Joy MT; Dinh A; Schottenfeld RS; Fiellin DA
    Drug Alcohol Depend; 2013 Jan; 127(1-3):243-7. PubMed ID: 22771144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medication-assisted treatment for opioid use disorder within a 12-step based treatment center: Feasibility and initial results.
    Klein AA; Seppala MD
    J Subst Abuse Treat; 2019 Sep; 104():51-63. PubMed ID: 31370985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of conventional, complementary, and alternative treatments for pain among individuals seeking primary care treatment with buprenorphine-naloxone.
    Barry DT; Savant JD; Beitel M; Cutter CJ; Moore BA; Schottenfeld RS; Fiellin DA
    J Addict Med; 2012 Dec; 6(4):274-9. PubMed ID: 23041680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid dependence treatment, including buprenorphine/naloxone.
    Raisch DW; Fye CL; Boardman KD; Sather MR
    Ann Pharmacother; 2002 Feb; 36(2):312-21. PubMed ID: 11847954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
    Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
    J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The changing face of opioid addiction: prescription pain pill dependence and treatment.
    Byrne MH; Lander L; Ferris M
    Health Soc Work; 2009 Feb; 34(1):53-6. PubMed ID: 19281102
    [No Abstract]   [Full Text] [Related]  

  • 8. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.
    Fiellin DA; Pantalon MV; Chawarski MC; Moore BA; Sullivan LE; O'Connor PG; Schottenfeld RS
    N Engl J Med; 2006 Jul; 355(4):365-74. PubMed ID: 16870915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of opioid-dependent adolescents and young adults with buprenorphine.
    Subramaniam GA; Fishman MJ; Woody G
    Curr Psychiatry Rep; 2009 Oct; 11(5):360-3. PubMed ID: 19785976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The multi-site prescription opioid addiction treatment study: 18-month outcomes.
    Potter JS; Dreifuss JA; Marino EN; Provost SE; Dodd DR; Rice LS; Fitzmaurice GM; Griffin ML; Weiss RD
    J Subst Abuse Treat; 2015 Jan; 48(1):62-9. PubMed ID: 25189089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults.
    Gonzalez G; DiGirolamo G; Romero-Gonzalez M; Smelson D; Ziedonis D; Kolodziej M
    Drug Alcohol Depend; 2015 Nov; 156():243-253. PubMed ID: 26454835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pain and associated substance use among opioid dependent individuals seeking office-based treatment with buprenorphine-naloxone: a needs assessment study.
    Barry DT; Savant JD; Beitel M; Cutter CJ; Moore BA; Schottenfeld RS; Fiellin DA
    Am J Addict; 2013; 22(3):212-7. PubMed ID: 23617861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid drug utilization and cost outcomes associated with the use of buprenorphine-naloxone in patients with a history of prescription opioid use.
    Kaur AD; McQueen A; Jan S
    J Manag Care Pharm; 2008 Mar; 14(2):186-94. PubMed ID: 18331120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical treatments for opioid use disorder in Iran: a randomized, double-blind placebo-controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment.
    Mokri A; Chawarski MC; Taherinakhost H; Schottenfeld RS
    Addiction; 2016 May; 111(5):874-82. PubMed ID: 26639678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population.
    McDermott KA; Griffin ML; Connery HS; Hilario EY; Fiellin DA; Fitzmaurice GM; Weiss RD
    J Clin Psychiatry; 2015 Feb; 76(2):189-94. PubMed ID: 25562462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.
    Parran TV; Adelman CA; Merkin B; Pagano ME; Defranco R; Ionescu RA; Mace AG
    Drug Alcohol Depend; 2010 Jan; 106(1):56-60. PubMed ID: 19717249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.
    Weiss RD; Potter JS; Fiellin DA; Byrne M; Connery HS; Dickinson W; Gardin J; Griffin ML; Gourevitch MN; Haller DL; Hasson AL; Huang Z; Jacobs P; Kosinski AS; Lindblad R; McCance-Katz EF; Provost SE; Selzer J; Somoza EC; Sonne SC; Ling W
    Arch Gen Psychiatry; 2011 Dec; 68(12):1238-46. PubMed ID: 22065255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buprenorphine-naloxone maintenance following release from jail.
    Lee JD; Grossman E; Truncali A; Rotrosen J; Rosenblum A; Magura S; Gourevitch MN
    Subst Abus; 2012; 33(1):40-7. PubMed ID: 22263712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid Addiction Treatment Using Buprenorphine-Naloxone In A Community-Based Internal Medicine Practice.
    Van Doren BA; Foulks-Rodriguez KA; Yarborough W
    J Okla State Med Assoc; 2015 Jul; 108(7):303-9. PubMed ID: 26390769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychiatric Comorbidity and Substance Use Outcomes in an Office-Based Buprenorphine Program Six Months Following Hurricane Sandy.
    Tofighi B; Grossman E; Goldfeld KS; Williams AR; Rotrosen J; Lee JD
    Subst Use Misuse; 2015; 50(12):1571-8. PubMed ID: 26623697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.